Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gala Health vs Navio MD

Gala Health
Graded #17

Higher grade

vs+13.100000000000009
Navio MD
Graded #112

Lower grade

The verdict

Gala Health takes it — 82.9/100 to 69.8/100.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +27
84
57
Dose & formulationGala Health +6
83
77
Clinical oversightNavio MD +2
85
87
Labs & monitoringGala Health +29
83
54
FulfillmentGala Health +3
88
85
Contract termsGala Health +11
66
55
Gala Health · left barNavio MD · right bar

The numbers

MetricGala HealthNavio MD
WeighScore82.9/10069.8/100
GradeB−C
Scorecard rank#17#112
SemaglutideNot disclosed$345/mo (starting dose, brand-name)
Tirzepatide$179/mo (yearly subscription)$189/mo (starting dose, compounded)
CoverageAll 50 states48 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Gala Health

Graded #17 · B−

Strengths

  • Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
  • Prices are published openly rather than quiz-gated, with all doses included at the one rate
  • All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet — injection only
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Navio MD

Graded #112 · C

Strengths

  • LegitScript verified with board-certified providers and US-licensed pharmacies
  • Both compounded and brand-name options
  • 48-state coverage
  • Hours 9am–10pm EST Mon–Sun
  • Transparent tiered pricing: you only pay for your current dose

Where it loses points

  • Not available in Alabama and Mississippi
  • Compounded option is tirzepatide only — no compounded semaglutide listed
  • Also offers women's HRT (broader platform)
  • Pricing is tiered by dose ('as low as'); the entry prices climb as your dose increases

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard